Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois Sells 2,824 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 2,824 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total value of $83,364.48. Following the completion of the transaction, the chief executive officer now directly owns 415,695 shares of the company’s stock, valued at $12,271,316.40. This represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cedric Francois also recently made the following trade(s):

• On Wednesday, January 22nd, Cedric Francois sold 13,551 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.43, for a total value of $412,356.93.
• On Friday, January 17th, Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total value of $179,969.72.
• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total value of $179,288.90.

Apellis Pharmaceuticals Stock Up 3.3 %

Shares of Apellis Pharmaceuticals stock traded up $0.99 on Thursday, reaching $30.46. 232,907 shares of the company were exchanged, compared to its average volume of 1,954,741. Apellis Pharmaceuticals, Inc. has a one year low of $24.34 and a one year high of $71.90. The company has a market capitalization of $3.79 billion, a price-to-earnings ratio of -14.99 and a beta of 0.94. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company has a 50-day moving average of $32.20 and a 200 day moving average of $32.96.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter last year, the company posted ($1.17) EPS. The firm’s revenue was up 78.3% on a year-over-year basis. On average, equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Oppenheimer decreased their target price on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group lowered Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective for the company. in a research report on Tuesday, December 17th. Needham & Company LLC decreased their price objective on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Bank of America decreased their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Evercore ISI upgraded Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $46.71.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in APLS. Wolverine Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter worth $27,000. True Wealth Design LLC bought a new position in Apellis Pharmaceuticals in the third quarter valued at about $27,000. Capital Performance Advisors LLP bought a new position in Apellis Pharmaceuticals in the third quarter valued at about $56,000. KBC Group NV raised its position in Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after purchasing an additional 679 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after purchasing an additional 781 shares during the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).